Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Non-Current Deffered Revenue (2021)

Historic Non-Current Deffered Revenue for Amylyx Pharmaceuticals (AMLX) over the last 1 years, with Q4 2021 value amounting to $35000.0.

  • Amylyx Pharmaceuticals' Non-Current Deffered Revenue changed N/A to $35000.0 in Q4 2021 from the same period last year, while for Dec 2021 it was $35000.0, marking a year-over-year change of. This contributed to the annual value of $35000.0 for FY2021, which is N/A changed from last year.
  • Amylyx Pharmaceuticals' Non-Current Deffered Revenue amounted to $35000.0 in Q4 2021.
  • Amylyx Pharmaceuticals' Non-Current Deffered Revenue's 5-year high stood at $35000.0 during Q4 2021, with a 5-year trough of $35000.0 in Q4 2021.